Clinical Trial Update: A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 study assessing the pharmacokinetics and safety of valganciclovir (Valcyte) in pediatric heart transplant recipients under 4 months old; the trial is re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cytomegalovirus Infections, Heart Transplantation | Phase 1 | Status: COMPLETED